收费全文 | 939990篇 |
免费 | 65154篇 |
国内免费 | 3265篇 |
耳鼻咽喉 | 12796篇 |
儿科学 | 29732篇 |
妇产科学 | 27168篇 |
基础医学 | 131061篇 |
口腔科学 | 25393篇 |
临床医学 | 78479篇 |
内科学 | 192568篇 |
皮肤病学 | 19650篇 |
神经病学 | 75046篇 |
特种医学 | 37813篇 |
外国民族医学 | 338篇 |
外科学 | 147281篇 |
综合类 | 21101篇 |
现状与发展 | 1篇 |
一般理论 | 248篇 |
预防医学 | 66782篇 |
眼科学 | 20621篇 |
药学 | 67338篇 |
8篇 | |
中国医学 | 2771篇 |
肿瘤学 | 52214篇 |
2019年 | 7451篇 |
2018年 | 10222篇 |
2017年 | 8131篇 |
2016年 | 8704篇 |
2015年 | 10037篇 |
2014年 | 14065篇 |
2013年 | 21248篇 |
2012年 | 28354篇 |
2011年 | 29994篇 |
2010年 | 18208篇 |
2009年 | 17281篇 |
2008年 | 28352篇 |
2007年 | 29990篇 |
2006年 | 29984篇 |
2005年 | 29434篇 |
2004年 | 28042篇 |
2003年 | 26931篇 |
2002年 | 26396篇 |
2001年 | 42304篇 |
2000年 | 43508篇 |
1999年 | 37140篇 |
1998年 | 10346篇 |
1997年 | 9422篇 |
1996年 | 9357篇 |
1995年 | 8675篇 |
1994年 | 8284篇 |
1993年 | 7748篇 |
1992年 | 28667篇 |
1991年 | 27397篇 |
1990年 | 26792篇 |
1989年 | 25736篇 |
1988年 | 23897篇 |
1987年 | 23473篇 |
1986年 | 22532篇 |
1985年 | 21380篇 |
1984年 | 16001篇 |
1983年 | 13629篇 |
1982年 | 8170篇 |
1979年 | 14743篇 |
1978年 | 10295篇 |
1977年 | 8705篇 |
1976年 | 8211篇 |
1975年 | 9031篇 |
1974年 | 10796篇 |
1973年 | 10284篇 |
1972年 | 9761篇 |
1971年 | 9009篇 |
1970年 | 8654篇 |
1969年 | 8108篇 |
1968年 | 7742篇 |
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献Methods: A retrospective analysis was performed to identify patients with isolated PCL injuries that underwent reconstruction between 2001 and 2014. Patients with multi-ligamentous injury or another concomitant knee pathology were excluded. Medical records were reviewed for demographic, clinical and operative data. Patients were contacted for administration of a telephone-based questionnaire which included the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation form, Lysholm-Tegner scales, Marx activity scale (MAS), return to sport status, and patient satisfaction instruments.
Results: A total of 15 isolated PCL reconstructions in 14 patients with a mean age of 27.5 years (range 17–43) met the study inclusion criteria; mean follow up was 6.3 years (range 1.4–15.2). Pre-operatively, the primary complaint was knee instability in all patients; on physical examination, lack of a firm end point during posterior drawer testing was found in 93% (14/15) of the knees. In total, 12 of 15 knees underwent transtibial, single-bundle PCLR and three of 15 underwent tibial inlay, double bundle PCLR. Graft types included: quadriceps autograft (7/15), Achilles allograft (6/15), and hamstring autograft (2/15). There were no graft failures in our patient cohort. At most recent follow up the mean scores respectively on the IKDC form, Lysholm-Tegner scales and MAS were (standard deviation): 77.3 (16.5), 83.1 (17.9), 6.13 (2.6), and 7.1 (6.0). All fourteen patients were athletes prior to their injury and 79% (11/14) returned to sport and overall patient satisfaction was 9.2/10.
Conclusions: Isolated PCLR provides good outcomes at mean medium-term follow up with restoration of function, high rate of return to sport and overall patient satisfaction. 相似文献